المؤلفون: Gontran Verset, James Lee, Sadahisa Ogasawara, Suresh Ratnam, Vittorina Zagonel, Angela Tatiana Alistar, Scot Ebbinghaus, Robin Kate Kelley, Chris Verslype, Daniel H. Palmer, Masatoshi Kudo, Olivier Rosmorduc, Ivan Borbath, Alan Weiss, Atisha Manhas, Carmine Pinto, Yutaka Sasaki, Yvonne Sada, Bruno Daniele, Laetitia Fartoux, Karl-Heinz Weiss, Daneng Li, Andrea L. Webber, Timothy Cannon, Gina M. Vaccaro, Per I Stal, Timothy Larson, Mukul Gupta, Jean-Frédéric Blanc, Simone I. Strasser, Kazushi Numata, Tatsuya Yamashita, David Cosgrove, Allen Lee Cohn, Ki Chung, Junshui Ma, Julien Edeline, Yoshivasu Karino, Jennifer J. Knox, Joerg Trojan, Debashis Sarker, Nevena Damjanov, Hans Van Vlierberghe, Richard S. Finn, Stephen L. Chan, Andreas Kaubisch, Jamil Asselah, Andrew X. Zhu, Magnus Rizell, Jena-Luc Van Laethem, Robert A. Ramirez, Mark Karwal, Gulam Abbas Manji, Ann-Lii Cheng, Arndt Vogel, Andrew Scott Paulson, Stéphane Cattan, Abby B. Siegel, Benjamin M. Parsons

المصدر: The Lancet Oncology. 19:940-952

مصطلحات موضوعية: Male, Sorafenib, medicine.medical_specialty, Carcinoma, Hepatocellular, Internationality, Pembrolizumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, Clinical endpoint, Humans, Neoplasm Invasiveness, Infusions, Intravenous, Survival rate, Aged, Neoplasm Staging, Dose-Response Relationship, Drug, business.industry, Liver Neoplasms, Remission Induction, Middle Aged, Prognosis, medicine.disease, Survival Rate, Oncology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, business, Progressive disease, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d63031639b53d0c366d883aa6d97a8e
https://doi.org/10.1016/s1470-2045(18)30351-6